Compared to insulin monotherapy, patients with T1DM who received amylin analog in addition to insulin experienced a greater reduction in pre-prandial hyperglycemia and a corresponding decrease in glucagon levels. This evidence concerns the gene IAPP and type 1 diabetes mellitus.